-

Bruker Corporation to Present at the 41st Annual J.P. Morgan Healthcare Conference

BILLERICA, Mass.--(BUSINESS WIRE)--Bruker Corporation (Nasdaq: BRKR) announced today it will participate in the 41st annual J.P. Morgan Healthcare Conference in San Francisco. Frank Laukien, Chairman, President & CEO, Mark Munch, Executive Vice President & President of Bruker Nano Group, and Gerald Herman, Executive Vice President & CFO will present on behalf of the Company on Monday, January 9th, 2023 at 10:30 AM Eastern Standard Time.

A live audio webcast of the presentation will be available on the Investor Relations section of the Company's website at https://ir.bruker.com. A replay of the presentation will be posted in the “Events & Presentations” section of the Bruker Corporation Investor Relations website after the event and will be available for 30 days following the presentation.

About Bruker Corporation (Nasdaq: BRKR)

Bruker is enabling scientists to make breakthrough discoveries and develop new applications that improve the quality of human life. Bruker’s high-performance scientific instruments and high-value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular, and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, improved productivity, and customer success in life science molecular research, in applied and pharma applications, in microscopy and nanoanalysis, and in industrial applications, as well as in cell biology, preclinical imaging, clinical phenomics and proteomics research and clinical microbiology. For more information, please visit: www.bruker.com.

Contacts

Investors:
Justin Ward
Senior Director, Investor Relations & Corporate Development
+1 (978) 663-3660 x1479
Investor.Relations@bruker.com

Bruker Corporation

NASDAQ:BRKR

Release Versions
$Cashtags
Hashtags

Contacts

Investors:
Justin Ward
Senior Director, Investor Relations & Corporate Development
+1 (978) 663-3660 x1479
Investor.Relations@bruker.com

Social Media Profiles
More News From Bruker Corporation

Bruker Reports Fourth Quarter and Full Year 2025 Financial Results

BILLERICA, Mass.--(BUSINESS WIRE)--Bruker Corporation (Nasdaq: BRKR) today announced financial results for its fourth quarter and for the full year ended December 31, 2025. Frank H. Laukien, Bruker’s President and CEO, commented: “At the conclusion of a difficult year 2025, with headwinds from academic funding, tariffs and currencies, we are pleased that in the fourth quarter we delivered revenues ahead of our expectations. A recovery in biopharma and industrial research markets in the second h...

Chemspeed and SciY Announce Self‑Driving Laboratory Platform Integrating Automation, Analytics and AI Orchestration

BOSTON--(BUSINESS WIRE)--At SLAS2026, Chemspeed Technologies, a leader in the automation and digitalization of R&D and QC laboratories, and SciY, a leader in scientific and laboratory management software focused on lab standardization and AI-readiness, today introduce their open Self‑Driving Lab (SDL) platform. Their Self-Driving Lab platform is designed to accelerate research and development (R&D), quality control (QC) and chemical and biomolecular manufacturing workflows. The SDL enab...

Bruker Introduces iNTApharma™, a Label‑Free Platform for Nanoparticle Characterization in mRNA Drug and Gene Therapy Development and QC

BILLERICA, Mass.--(BUSINESS WIRE)--Bruker Corporation today announced the launch of iNTApharma, a label‑free characterization platform that provides single‑particle sensitivity for the quantitative analysis of nanoscale bioparticles in native aqueous media. Introduced at SLAS 2026 in Boston, iNTApharma delivers size and concentration measurements within minutes, supporting research, therapy development and quality control workflows that require direct, native‑state assessment of bio-nanoparticl...
Back to Newsroom